FDA vs Health Canada Cosmetic Regulations: A Technical Comparison of Compliance Requirements for Cosmetic Products

Companies planning to commercialize cosmetic products in North America frequently target both the United States and Canada due to their large consumer markets and strong distribution networks. Although these markets are geographically close, cosmetic regulatory frameworks in the United States and Canada differ significantly in terms of ingredient restrictions, labeling requirements, facility obligations, and regulatory notifications.

Understanding these regulatory differences is critical for cosmetic manufacturers, brand owners, importers, and distributors seeking to avoid compliance risks such as product detentions, enforcement actions, or product recalls.

This article provides a technical comparison of cosmetic compliance requirements under the United States Food and Drug Administration (FDA) framework and Health Canada’s cosmetic regulatory system.

Regulatory Framework Governing Cosmetics

In the United States, cosmetic products are regulated by the Food and Drug Administration (FDA) under the Federal Food, Drug and Cosmetic Act (FD&C Act) and more recently under the Modernization of Cosmetics Regulation Act (MoCRA), which introduced new compliance obligations for cosmetic companies.

In Canada, cosmetics are regulated by Health Canada under the Food and Drugs Act and the Cosmetic Regulations, which establish requirements related to safety, ingredient restrictions, product notification, and labeling.

While both jurisdictions prioritize consumer safety, their regulatory approaches differ in structure and enforcement mechanisms.

Ingredient Restrictions and Safety Substantiation

Ingredient compliance is a critical aspect of cosmetic regulation in both jurisdictions.

Health Canada maintains a Cosmetic Ingredient Hotlist, which identifies substances that are either prohibited or restricted in cosmetic formulations. Companies must ensure that products marketed in Canada do not contain ingredients that violate the conditions listed in the Hotlist. For restricted ingredients, manufacturers must comply with concentration limits, warning statements, or usage restrictions.

The United States FDA does not maintain a single comprehensive prohibited ingredient list comparable to Canada’s Hotlist. Instead, the regulatory system relies on general safety provisions under the FD&C Act. Under MoCRA, cosmetic companies are now required to maintain adequate safety substantiation for cosmetic products, demonstrating that formulations are safe under the intended conditions of use.

Companies selling cosmetics in both markets must therefore conduct ingredient compliance reviews to ensure that formulations meet both Canadian Hotlist restrictions and FDA safety substantiation requirements.

Cosmetic Product Notification and Regulatory Filing

A key regulatory difference between the two jurisdictions relates to market notification requirements.

In Canada, cosmetic products must be notified to Health Canada through a Cosmetic Notification Form (CNF) within 10 days after the product is first sold in the Canadian market. The CNF submission includes product details, ingredient information, and manufacturer or importer information.

In contrast, the United States historically did not require mandatory cosmetic product notifications. However, under MoCRA, cosmetic companies must now complete FDA cosmetic product listings and facility registrations, introducing additional regulatory transparency.

Foreign manufacturers supplying cosmetics to the US market must ensure that their manufacturing facilities are properly registered with the FDA and that products are listed within the FDA system.

Labeling Requirements: Canadian Bilingual Rules vs U.S. Labeling Standards

Cosmetic labeling is another area where regulatory requirements differ substantially.

Health Canada requires cosmetic product labels to include bilingual labeling in English and French, reflecting Canada’s official languages. Mandatory label information includes:

• Product identity
• Net quantity declaration
• Ingredient list using INCI nomenclature
• Manufacturer or distributor information
• Warning statements where applicable

Failure to comply with bilingual labeling requirements is one of the most common causes of regulatory non-compliance for cosmetics sold in Canada.

In the United States, FDA cosmetic labeling regulations require:

• Declaration of ingredients in descending order of predominance
• Identification of the responsible person
• Product identity statement
• Net quantity declaration
• Manufacturer, packer, or distributor information

MoCRA has further strengthened labeling transparency by introducing additional regulatory expectations for cosmetic product identification and adverse event reporting.

Responsible Person and Regulatory Accountability

Under MoCRA, cosmetic products marketed in the United States must designate a Responsible Person, typically the manufacturer, brand owner, or distributor whose name appears on the product label.

The Responsible Person must ensure compliance with FDA requirements, maintain safety substantiation records, and report serious adverse events associated with cosmetic products.

In Canada, while the term “Responsible Person” is not formally defined in the same way, regulatory accountability generally falls on the Canadian manufacturer or importer of record, who is responsible for submitting the Cosmetic Notification Form and ensuring product compliance.

Companies exporting cosmetics into Canada may therefore require a Canadian importer or regulatory representative to maintain compliance with Health Canada requirements.

Regulatory Enforcement and Penalties

Both the FDA and Health Canada maintain enforcement authority to ensure cosmetic safety and regulatory compliance.

The FDA can take enforcement actions including warning letters, import alerts, product seizures, injunctions, and mandatory recalls when cosmetic products are found to be adulterated, misbranded, or unsafe.

Health Canada may enforce compliance through product recalls, stop-sale orders, product seizures, and regulatory inspections, particularly when products contain restricted ingredients or fail to meet labeling requirements.

Failure to meet regulatory obligations can also lead to product detentions at the border, particularly for imported cosmetics entering North American markets.

Strategic Compliance for Brands Entering North America

Cosmetic brands expanding into North America must adopt a jurisdiction-specific regulatory strategy. While the US and Canadian markets may appear similar from a commercial perspective, regulatory compliance requirements differ significantly in terms of ingredient restrictions, labeling obligations, and product notification systems.

Companies that proactively align their regulatory strategy with both FDA and Health Canada expectations can significantly reduce compliance risks and accelerate market entry.

How Fiducia Globus Supports Cosmetic Compliance

Fiducia Globus supports cosmetic brands, manufacturers, and importers navigating regulatory compliance across the United States and Canada.

Our services include FDA MoCRA facility registration, cosmetic product listing, Health Canada Cosmetic Notification submissions, ingredient compliance assessments, labeling reviews, and regulatory strategy support for cosmetic market entry.

By providing practical regulatory guidance and compliance support, Fiducia Globus helps cosmetic companies enter North American markets with confidence while maintaining full regulatory compliance.